
    
      The study will include 12 secondary progressive multiple sclerosis patients and 12 primary
      progressive multiple sclerosis patients to treatment with IV natalizumab for 60 weeks. At
      baseline and week 60 a lumbar puncture will be performed. MRI scans will be performed at
      baseline week 12 and week 60.Safety blood samples will be collected every 12 week.
    
  